Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats

被引:27
作者
Ben-Dov, Iddo Z.
Pappo, Orit
Sklair-Levy, Miri
Galitzer, Hillel
Ilan, Yaron
Naveh-Many, Tally
Silver, Justin
机构
[1] Hadassah Hebrew Univ Med Ctr, Minerva Ctr Calcium & Bone Metab, Nephrol & Hypertens Serv, IL-91120 Jerusalem, Israel
[2] Hadassah Hebrew Univ Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel
[3] Hadassah Hebrew Univ Med Ctr, Dept Radiol, IL-91120 Jerusalem, Israel
[4] Hadassah Hebrew Univ Med Ctr, Liver Unit, IL-91120 Jerusalem, Israel
关键词
chronic kidney disease; gene expression; hyperphosphataemia; lanthanum carbonate; phosphate binders; secondary hyperparathyroidism;
D O I
10.1093/ndt/gfl623
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Lanthanum (La) carbonate is an effective phosphate-binder, used to reverse hyperphosphataemia due to chronic kidney disease. Some recent studies in rodents have cast safety uncertainties. The aims of this study were to examine the effects of La on parathyroid hormone (PTH) gene expression and hepatic toxicity. Methods. Uraemia was induced in rats by a 0.3% adenine-containing diet for 2 weeks. Thereafter, rats were maintained for 4 weeks on an adenine diet with 1.5 or 3% La. Normal, uraemic, and uraemic rats fed a low-phosphorus (P) diet served as controls. Results. Azotaemia developed in all adenine-fed rats. La of 3%, but not 1.5% La, decreased serum P to normal in uraemic rats. Both La 1.5 and 3% decreased urine P excretion. Plasma PTH was tripled in uraemic compared with normal rats. Both the 3.0% La and the low-P diet decreased PTH to normal. PTH mRNA content was increased 2-fold in uraemic compared with normal rats. The 3% La or the low-P diet decreased PTH mRNA levels to normal in uraemic rats. Liver enzymes were normal in all groups. Adenine-induced uraemia decreased liver weight with no additional effect of La. Liver weights corrected for body-weights were the same in all study groups, including the La group. Therefore, La had no effect upon absolute or corrected liver weight. Liver magnetic resonance imaging and microscopy did not reveal toxic changes due to La. Conclusions. These findings confirm that in rats with adenine-induced uraemia, the P-binder La reverses the hyperphosphataemia and hyperparathyroidism. They are the first demonstration that La decreases PTH gene expression. Importantly, we found no evidence of drug-induced liver toxicity.
引用
收藏
页码:362 / 368
页数:7
相关论文
共 18 条
[1]  
Almaden Y, 1996, J BONE MINER RES, V11, P970
[2]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[3]  
Chiang SS, 2005, CLIN NEPHROL, V63, P461
[4]   Management of secondary hyperparathyroidism [J].
Cunningham, J .
THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 :S35-S40
[5]  
DAHAESE PC, 2003, KIDNEY INT S, pS73
[6]   Evaluation of the potential genotoxicity of the phosphate binder lanthanum carbonate [J].
Damment, SJP ;
Beevers, C ;
Gatehouse, DG .
MUTAGENESIS, 2005, 20 (01) :29-37
[7]  
Finn WF, 2004, CLIN NEPHROL, V62, P193
[8]   Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure [J].
González-Suárez, I ;
Naves, M ;
Díaz-Corte, C ;
Fernández-Martín, JL ;
Menéndez-Rodríguez, P ;
Cannata-Andía, JB .
KIDNEY INTERNATIONAL, 2003, 63 :S39-S43
[9]   Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia:: A 6-month, randomized, comparative trial versus calcium carbonate [J].
Hutchison, AJ ;
Maes, B ;
Vanwalleghem, J ;
Asmus, G ;
Mohamed, E ;
Schmieder, R ;
Backs, W ;
Jamar, R ;
Vosskühler, A .
NEPHRON CLINICAL PRACTICE, 2005, 100 (01) :C8-C19
[10]   Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia [J].
Joy, MS ;
Finn, WF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (01) :96-107